Exagen Inc. (NASDAQ:XGN) Given Average Recommendation of "Moderate Buy" by Brokerages
Exagen Inc. (NASDAQ:XGN - Get Free Report) has earned an average rating of "Moderate Buy" from the ten analysts that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation and nine have assigned a buy recommendation to the compan...
MarketBeat·6d ago
More News
Exagen Inc. (NASDAQ:XGN) Short Interest Update
Exagen Inc. (NASDAQ:XGN - Get Free Report) was the recipient of a large increase in short interest in the month of February. As of February 27th, there was short interest totaling 1,071,934 shares...
MarketBeat·20d ago
Exagen (NASDAQ:XGN) Downgraded by Wall Street Zen to Sell
Wall Street Zen cut Exagen from a "hold" rating to a "sell" rating in a report on Saturday...
MarketBeat·22d ago
Canaccord Genuity Group Issues Pessimistic Forecast for Exagen (NASDAQ:XGN) Stock Price
Canaccord Genuity Group dropped their price objective on shares of Exagen from $15.00 to $10.00 and set a "buy" rating on the stock in a report on Wednesday...
MarketBeat·25d ago
Exagen (NASDAQ:XGN) Price Target Cut to $10.00 by Analysts at Craig Hallum
Craig Hallum decreased their price objective on shares of Exagen from $12.00 to $10.00 and set a "buy" rating for the company in a research report on Wednesday...
MarketBeat·25d ago
KeyCorp Issues Pessimistic Forecast for Exagen (NASDAQ:XGN) Stock Price
KeyCorp cut their price target on Exagen from $15.00 to $10.00 and set an "overweight" rating for the company in a research note on Wednesday...
MarketBeat·25d ago
Exagen (NASDAQ:XGN) Price Target Lowered to $9.00 at BTIG Research
BTIG Research cut their price target on shares of Exagen from $10.00 to $9.00 and set a "buy" rating for the company in a report on Tuesday...
MarketBeat·25d ago
Exagen Q4 Earnings Call Highlights
Exagen (NASDAQ:XGN) executives said the company closed 2025 with record revenue and testing volume, pointing to progress from operational changes made over the past several years, while acknowledging...
MarketBeat·26d ago
Exagen Inc. (XGN) Reports Q4 Loss, Beats Revenue Estimates
Exagen (XGN) delivered earnings and revenue surprises of 0.00% and +1.62%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·26d ago
Myomo, Inc. (MYO) Reports Q4 Loss, Tops Revenue Estimates
Myomo (MYO) delivered earnings and revenue surprises of +5.88% and +11.86%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?